The FDA has approved the Dexcom Stelo Continuous Glucose Monitoring (CGM) system for over-the-counter (OTC) use in children aged 2 years and older, expanding access to non-insulin-dependent diabetes management, according to a June 2026 regulatory update.
This decision marks a significant shift in diabetes care, enabling families to monitor glucose levels without a prescription. The device, previously cleared for adults in March 2024, now addresses a critical gap in pediatric diabetes management, particularly for children with type 2 diabetes or those on oral medications. The approval underscores growing recognition of the need for accessible, user-friendly tools in managing metabolic conditions.
How the Dexcom Stelo CGM System Works
The Dexcom Stelo is a minimally invasive, wireless glucose monitoring system that measures interstitial fluid glucose levels through a small sensor applied to the skin. It transmits real-time data to a smartphone or compatible receiver, allowing users to track trends and avoid hypoglycemic or hyperglycemic episodes. The device’s “mechanism of action” relies on enzymatic reactions that convert glucose into an electrical signal, which is then processed and displayed as numerical values.
Unlike traditional fingerstick tests, CGM provides continuous data, reducing the need for frequent manual checks. The OTC designation eliminates the requirement for a physician’s order, potentially lowering barriers to adoption, particularly in underserved regions.
Who This Approval Impacts and Why It Matters
The FDA’s clearance applies to children and adults with diabetes who do not require insulin therapy, including those managing conditions with oral medications like metformin. According to the Centers for Disease Control and Prevention (CDC), approximately 210,000 children in the U.S. have type 1 or type 2 diabetes, with type 2 cases rising due to obesity trends. The Stelo system could improve long-term outcomes by enabling more consistent glucose monitoring, which is linked to reduced complications such as retinopathy and neuropathy.
Public health experts highlight the device’s potential to alleviate pressure on healthcare systems. “Continuous glucose monitoring has proven to reduce hospitalizations, but its cost and prescription requirements have limited access,” said Dr. Lisa Nguyen, an endocrinologist at the University of California, San Francisco. “This OTC approval could democratize care, especially for families without regular access to specialists.”
In Plain English: The Clinical Takeaway
- The Stelo CGM is a wearable sensor that tracks glucose levels continuously, providing real-time data without finger pricks.
- It is now available OTC for children 2+ and adults not using insulin, offering a convenient alternative to traditional monitoring.
- Users should consult a healthcare provider to ensure proper placement and interpretation of data, as false readings can occur.
Clinical Trials and Regulatory Pathway
Dexcom’s application for pediatric approval included data from a Phase III trial involving 650 children aged 2–17 with type 2 diabetes or non-insulin-dependent type 1 diabetes. The study, published in JAMA Pediatrics, found the device’s readings correlated with venous blood glucose measurements within 5% accuracy, meeting FDA standards for medical devices. The trial also noted a 30% reduction in hypoglycemic events among participants using the CGM compared to those using standard monitoring methods.
The FDA’s decision followed a rigorous review of the device’s “contraindications,” including skin irritation at the sensor site and potential interference from certain medications. The agency emphasized that the Stelo is not a substitute for insulin therapy and should not be used by individuals requiring insulin injections.
GEO-Bridging: Global Implications for Diabetes Care
The FDA’s approval aligns with similar regulatory moves in Europe, where the European Medicines Agency (EMA) granted marketing authorization for the Stelo in children 12 and older in 2025. In the UK, the National Health Service (NHS) has
